Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Font Size

Drug Extends Prostate Cancer Survival

Hormone Treatment Offers 4 Extra Months in Metastatic Prostate Cancer
WebMD Health News
Reviewed by Laura J. Martin, MD

Oct. 12, 2010 -- Even when medical or surgical castration fails, a potent drug extends survival by four months in patients with metastatic prostate cancer.

The drug is Johnson & Johnson's abiraterone acetate. It blocks an enzyme crucial to the production of male hormones, which spur the growth and spread of advanced prostate cancers.

The treatment gave patients with metastatic, castration-resistant prostate cancer only an extra four months of life. But there's more hope than that from the study of some 1,200 men with late-stage cancer at 147 medical centers in 13 nations. The study was funded by Johnson & Johnson, which is developing the drug.

It appears that abiraterone is able to shut down androgen production not only in the testes, but also from the adrenal gland and from within prostate tumors themselves.

And while the average patient survived only four months longer than those on standard chemotherapy -- 14.8 months vs. 10.9 months -- some patients did much better.

"A key question now is to work out which patients will benefit from the drug -- clearly, some patients do and some don't," Johann de Bono, MD, PhD, of the U.K.'s Royal Marsden NHS Foundation Trust, says in a news release.

De Bono reported the study findings in at this week's meeting of the European Society for Medical Oncology in Milan, Italy.

This study was presented at a medical conference. The findings should be considered preliminary as they have not yet undergone the "peer review" process, in which outside experts scrutinize the data prior to publication in a medical journal.

Today on WebMD

man with doctor
Symptoms, risks, treatments
man coughing
Men shouldn’t ignore
prostate cancer cells
What does this diagnosis mean?
doctor and male patient
Is it worth it?
cancer fighting foods
15 Cancer Symptoms Men Ignore
Prostate Enlarged
Picture Of The Prostate
Prostate Cancer Quiz
screening tests for men
Prostate Cancer Symptoms
Vitamin D